European Hematology Association

Organization

Publications in OpenAlex of which a co-author is affiliated to this organization

All publications | By field | By subfield

All publications [Next]
Title DOI
https://doi.org/10.1681/asn.2015050542 CKD Prevalence Varies across the European General Population
https://doi.org/10.1038/nrneph.2017.52 The systemic nature of CKD
https://doi.org/10.1093/ndt/gfv209 How to routinely collect data on patient-reported outcome and experience measures in renal registries in Europe: an expert consensus meeting
https://doi.org/10.1128/jcm.00873-23 A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC
https://doi.org/10.1097/hs9.0000000000000900 Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance
https://doi.org/10.1097/hs9.0000000000000524 Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
https://doi.org/10.1097/hs9.0000000000000842 A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care
https://doi.org/10.1016/s2352-3026(23)00182-5 Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective
https://doi.org/10.1097/hs9.0000000000000488 Fair Pricing of Innovative Medicines: An EHA Position Paper
https://doi.org/10.1111/nicc.13074 European federation of Critical Care Nursing associations (EfCCNa) position statement: Towards sustainable intensive care
https://doi.org/10.3389/froh.2025.1577870 Career aspirations of dental students: insights from a multinational study using social cognitive career theory (SCCT)
https://doi.org/10.3389/fimmu.2025.1567582 European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring
https://doi.org/10.2215/cjn.02000311 Improvement in the Renal Prognosis in Nephropathic Cystinosis
https://doi.org/10.3324/haematol.2015.136739 The European Hematology Association Roadmap for European Hematology Research: a consensus document
https://doi.org/10.1002/ece3.1831 Pedigree analysis for the genetic management of group‐living species
https://doi.org/10.1136/esmoopen-2019-000611 EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
https://doi.org/10.1097/hs9.0000000000000724 Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force
https://doi.org/10.1136/rmdopen-2021-001710 Suitability for e-health of non-pharmacological interventions in connective tissue diseases: scoping review with a descriptive analysis
https://doi.org/10.1038/s41409-023-02072-7 Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy—a guidance by the GoCART Coalition Pharmacist Working Group
https://doi.org/10.3324/haematol.2016.142018 Blood disorders stepping into the limelight
https://doi.org/10.1016/j.drudis.2024.104251 Stimulating development of innovative medicines in the European Union: does a new definition for unmet medical need add value?
https://doi.org/10.1007/s00464-025-11749-7 A systematic review, meta-analysis and GRADE assessment of the evidence on complete mesocolic excision for right-sided colon cancer with SAGES and ESCP participation
https://doi.org/10.3390/jmahp12030011 The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and Survey of the European Access Academy
https://doi.org/10.3324/haematol.2014.104299 Survey of professional competence in hematology in Europe
https://doi.org/10.1097/hs9.0000000000000865 Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities
https://doi.org/10.1111/trf.17764 The 2023 AABB international guidelines for red blood cell transfusions: What is new?
https://doi.org/10.1038/s41746-025-02113-z Reporting guidelines for studies involving generative artificial intelligence applications: what do I use, and when?
https://doi.org/10.3390/jmahp13010006 Avoiding Error and Finding the Right Balance in European Health Technology Assessments: Insights Generated by the European Access Academy
https://doi.org/10.1002/hem3.70226 Burnout symptoms among hematology professionals: An EHA survey
https://doi.org/10.1128/jcm.01625-23 Reply to Kidd et al., “Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion”
https://doi.org/10.1111/eje.13123 Recommendations for Enhancing Oral Health Professional Education Through the Student Voice: The ADEE ‐ EDSA Partnership in Action
https://doi.org/10.1002/hem3.70204 Bridging gaps in clinical trial accessibility and reimbursement for large B‐cell lymphoma therapies across Europe
https://doi.org/10.1038/s41591-025-04055-1 Reduce bureaucracy in clinical trials now
https://doi.org/10.1159/000031173 Results of Viral Marker Screening of Unpaid Blood Donations and Probability of Window Period Donations in 1997
https://doi.org/10.1111/hequ.12381 Europe's post‐pandemic internationalisation: Challenges and possibilities in a decidedly networked future
https://doi.org/10.3324/haematol.2012.078964 H-Net, the European Network for Harmonization of Training in Hematology, and its policy
https://doi.org/10.3324/haematol.2012.067942 Towards a joint definition of European hematology
https://doi.org/10.1016/s2352-3026(16)30074-6 Costs of haematological disease high and rising
https://doi.org/10.1586/ehm.10.55 15th Congress of European Hematology Association
https://doi.org/10.1515/cclm-2022-1051 The gaps between the new EU legislation on in vitro diagnostics and the on-the-ground reality
https://doi.org/10.4000/mots.21281 Le discours promotionnel des universités européennes. Homogénéité dans la compétitivité ?
https://doi.org/10.3324/haematol.2013.103424 Remembering John M. Goldman
https://doi.org/10.3324/haematol.2013.090415 Age and aging in blood disorders: EHA theme of the year 2013-2014
https://doi.org/10.1049/bme2.12107 Facilitating free travel in the Schengen area—A position paper by the European Association for Biometrics
https://doi.org/10.3324/haematol.2012.080796 Quality of Life in hematology: European Hematology Association theme of the year ... and years to come
https://doi.org/10.1186/s12909-020-02364-2 The MD-PhD program in Geneva: a 10-year analysis of graduate demographics and outcomes
https://doi.org/10.1097/hs9.0000000000000477 Access to Affordable Orphan Medicines in Europe: An EHA Position Paper
https://doi.org/10.1111/eje.12917 The views of European students on the inclusion of research in undergraduate Oral Health Professional curricula
https://doi.org/10.1111/j.1365-2478.1977.tb01175.x UNITS AND DIMENSIONS IN SCIENTIFIC PUBLICATIONS*
https://doi.org/10.1177/00178969211035169 Co-creating an empowering health education intervention for urological cancer patients
https://doi.org/10.1027/2192-0923/a000245 A Competency Framework for Aviation Psychologists and Human Factors Specialists in Aviation
https://doi.org/10.1097/hs9.0000000000000291 The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe
https://doi.org/10.1016/j.jval.2022.04.1729 Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools
https://doi.org/10.3324/haematol.2011.057257 Raising hematology's European voice: the importance of calling yourself a hematologist
https://doi.org/10.1093/eurpub/ckv174.031 Injury Surveillance Platform
https://doi.org/10.1097/hs9.0000000000000298 Delivering on the Promise: Innovative Therapies and the Quest for (Real) Patient Benefit
https://doi.org/10.1097/hs9.0000000000000702 Addressing Inequality of Access to Biologics: What Is Your Role? A Patient (Advocate)’s Perspective on Biosimilars
https://doi.org/10.1002/hem3.70108 European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies
https://doi.org/10.1002/hem3.70239 Patient‐centered and proportionate safety reporting in clinical trials facilitates evidence‐based medicine for the benefit of patients and society: An EHA priority
https://doi.org/10.1046/j.1423-0410.2000.7830149.x Results of Viral Marker Screening of Unpaid Blood Donations and Probability of Window Period Donations in 1997
https://doi.org/10.1177/089686080002002s23 The European Registry: Where do We Stand?
https://doi.org/10.1097/hs9.0000000000000012 Affordability of Medicines a Top Priority for EHA: Toward a Fair Pricing Model for Innovative Medicines
https://doi.org/10.1097/hs9.0000000000000049 The European Hematology Curriculum: An Electronic Passport Promoting Professional Competence and Mobility
https://doi.org/10.18620/ctt-1866-8836-2019-8-2-82-90 Highlights of the 24th European Hematology Association Congress, Amsterdam 2019
https://doi.org/10.1097/hs9.0000000000000354 Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished—What is Next?
https://doi.org/10.12816/0003166 Chronic Myeloid Leukaemia : A Paradigm for Malignancy or Just a Strange Disease ? = الإبيضاض النخاعي المزمن : نموذج لورم خبيث أو مجرد مرض غريب ؟
https://doi.org/10.1080/17457300902836689 Call for cross governmental leadership to strategic cooperation among multiple stakeholders in preventing injuries in Europe: Conclusions of the 2nd European Conference on Injury Prevention and Safety Promotion, 9–10 October 2008
https://doi.org/10.1159/000479547 Making Change Happen in Health
https://doi.org/10.1159/000481565 The Long and the Short of Missing Medicines
https://doi.org/10.1097/hs9.0000000000000765 How a Medical Association Can Make a Difference in a Crisis Situation
https://doi.org/10.1182/blood-2022-157549 Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
https://doi.org/10.1097/hs9.0000000000000365 EHA Scientific Working Groups: Connecting Science and Spreading Knowledge in Hematology
https://doi.org/10.1159/000031050 Nucleic Acid Amplification Tests for the Detection of Blood–Borne Viruses
https://doi.org/10.1046/j.1423-0410.1999.7630194.x Nucleic Acid Amplification Tests for the Detection of Blood‐Borne Viruses
https://doi.org/10.1006/biol.1999.0231 Sixth EPFA/NIBSC Workshop on NAT in Rome 1999: Outcome of Discussions†
https://doi.org/10.1080/01436598208419643 The new conservatism in the West
https://doi.org/10.1097/00007691-199508000-00140 128 ANALYSIS AND DOSING OF ANTIBIOTICS IN A RENAL PATIENT
https://doi.org/10.1111/j.1467-8691.1995.tb00204.x Letter from Heerlen
https://doi.org/10.12968/hmed.2015.76.8.442 European Hematology AssoCiation Vienna, austria, 11–14 June
https://doi.org/10.1097/hs9.0000000000000017 Hematology and Big Data: Enabling Better and Faster Treatment
https://doi.org/10.1097/hs9.0000000000000046 How Talent Acceleration Generated Talent Advocacy
https://doi.org/10.1016/j.ekir.2019.05.047 SAT-025 DATA ITEM COLLECTION BY RENAL REGISTRIES AROUND THE WORLD – RESULTS FROM THE SharE-RR SURVEY
https://doi.org/10.29328/journal.ijbmr.1001011 Novel European Asiatic Clinical, Laboratory, Molecular and Pathobiological (2015-2020 CLMP) criteria for JAK2V617F trilinear polycythemia vera (PV), JAK2exon12 PV and JAK2V617F, CALR and MPL515 thrombocythemias: From Dameshek to Constantinescu-Vainchenker, Kralovics and Michiels
https://doi.org/10.1097/hs9.0000000000000500 Change is Coming: Plan S From the Early Career Scientist Perspective
https://doi.org/10.1093/ndt/gfab092.0027 MO149PREGNANCY AFTER LIVING KIDNEY DONATION, A SYSTEMATIC REVIEW OF THE AVAILABLE EVIDENCE AND A REVIEW OF THE CURRENT GUIDANCE
https://doi.org/10.1093/eurpub/ckab164.664 The influence of the COVID-19 pandemic on the prevalence of severe injuries in The Netherlands
https://doi.org/10.1182/blood-2021-145002 Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance
https://doi.org/10.1007/978-3-030-94353-0_43 GoCART
https://doi.org/10.1111/j.1467-8691.1994.tb00174.x Letter from Heerlen
https://doi.org/10.1006/biol.1999.0220 Editorial
https://doi.org/10.1002/9781118625392.wbecp088 Gestalt Therapy
https://doi.org/10.1097/hs9.0000000000000743 The Updated European Hematology Association Research Roadmap
https://doi.org/10.1097/01.hs9.0000848632.89484.3a P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION
https://doi.org/10.1097/hs9.0000000000000777 The Renovated Face of EHA Classical Master Class: A Survey-based Evaluation on Behalf of the EHA Campus Working Group
https://doi.org/10.1097/hs9.0000000000000815 The Progress Test of the European Hematology Association: A New Tool for Continuous Learning
https://doi.org/10.35376/10324/59908 Importancia del perfil inflamatorio-molecular en la infección por SARS-COV-2 y su relación con el grupo sanguíneo ABO.
https://doi.org/10.1016/j.jval.2023.09.241 CO169 Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies in the Framework of the EU Project, Harmony: the Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology
https://doi.org/10.21203/rs.3.rs-3961968/v1 Delphi hackathon – a new approach to develop Core Outcome Sets for blood cancers
https://doi.org/10.1016/j.jcyt.2024.03.223 T2EVOLVE: STANDARDIZATION OF PRE-CLINICAL AND CLINICAL DEVELOPMENT OF ENGINEERED T CELL THERAPY IN EUROPE; A CROSS FUNCTIONAL MULTI STAKEHOLDER INITIATIVE
https://doi.org/10.33590/emjhematol/pgqp6795 EHA Congress Interview: Elizabeth Macintyre